Drug Profile
KW 2478
Alternative Names: KW-2478Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Developer Kyowa Hakko Kirin
- Class Antineoplastics; Morpholines
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Multiple myeloma
Most Recent Events
- 27 Apr 2011 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line or greater therapy) in Philippines (IV) (NCT01063907)
- 31 Jan 2011 Kyowa Hakko Kirin completes a phase I trial in Haematological malignancies in the United Kingdom (NCT00457782)
- 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin